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Objective: To determine the prevalence and site of isolation of different serotypes of group B streptococcus
(GBS) colonization or infection at a small community hospital.
Methods: GBS isolates were obtained from a small community hospital and were then serotyped as la, Ib, II, III, IV,
V or nontypeable. Hospital records were reviewed for patient sex, age and pregnancy status as well as the site of
GBS isolation.
Results: GBS serotypes Ia, III and V were most common and accounted for over 60% of the total number of
isolates. Serotype Ia was most prevalent in reproductive-age females, while serotypes V and III were most prevalent
in non-reproductive-age females and males, respectively. Serotype la was most frequent in both pregnant and
nonpregnantfemales. Serotype IV was more common in this studypopulation than in those from other locations.
Conclusions: The GBS serotype distribution in this small community did not differ significantly from distributions
described in larger North American centers. A GBS vaccine designed against multiple serotypes would be
protective for most of this population.
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INTRODUCTION
Group B streptococcus (GBS) is the primary bac-
terial agent causing neonatal infections, including
pneumonia, meningitis and sepsis. This organism
has also been implicated in adult disease including
postpartum infections, urinary tract infections, soft
tissue infections and pneumonia1. While prophy-
lactic antibiotic treatment implemented by many
obstetricians has resulted in a significant reduction
in infant morbidity and mortality, it does not
address protection of the infant during the first
critical months after birth or prevention of adult
GBS disease. Vaccine development resulting in the
generation of GBS-specific antibody is the strategy
of choice. For effective vaccine design, identifica-
tion of the most prevalent serotypes isolated from
the general population is required. In the present
study we determined the prevalence of GBS
serotypes in a community hospital and compared
these data to studies from larger centers in North
America.
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SUBJECTS AND METHODS
Study population
Medical records were reviewed from 107 patients
who were identified as GBS-culture-positive by
the Cabell Huntington Hospital microbiology
laboratory (Huntington, WV) from August to
November 1999. Patients were classified by retro-
spective chart review according to sex, age, preg-
nancy status, previous positive GBS culture and
the site of GBS isolation. One hundred and two
of the isolates were from females while only five
isolates were from males. Patients ranged in age
from 18 months to 92 years old. Nonreproductive
age females were defined as 18 months to 13 years
of age and from 40–92 years of age. Information on
race for this population was not available; how-
ever, the majority of the communities that are
served by this hospital are Caucasian. The most
common site of isolation was from genital or urine
cultures of reproductive-age females. GBS was also
isolated from nonurogenital surfaces including a
foot wound, endotracheal tube secretions, blood, a
peritonsilar abscess and throat cultures.
GBS isolation
Bacterial cultures obtained from the hospital were
streaked on 5% sheep blood tryptic soy agar plates
and incubated overnight at 37°C in 5% CO2 to
establish a pure GBS culture. A single colony from
each plate was inoculated into Todd Hewitt broth
(THB) and incubated overnight at 37°C in 5%
CO2. The overnight cultures were mixed 1:1
(volume:volume) with 24% sterile glycerol and
frozen at -20°C until use.
GBS serotype determination
GBS were serotyped using a hemolytic strepto-
coccus group B typing sera kit (Accurate Chemical
& Scientific Corporation, Westbury, NY) accord-
ing to manufacturer’s instructions. Briefly, 10 ml of
GBS culture from frozen stocks were inoculated
into 5 ml THB and incubated overnight at 37°C in
5% CO2. The overnight cultures were centrifuged
at 1400 ´ g for 20 minutes. After discarding the
supernatant, the GBS pellet was suspended in
0.5 ml THB. Digestive enzymes from swine
pancreas extracts were added to the GBS suspen-
sion prior to incubation at 37°C for 1 hour. The
GBS suspension was centrifuged at 1400 ´ g for
20 minutes. The bacterial pellet was suspended
in 0.5 ml phosphate-buffered saline (PBS) and
incubated at 120°C for 30 minutes. Serotyping of
the GBS extract was accomplished by agglutina-
tion with serotype-specific antisera (Ia, Ib, II, III,
IV or V). PBS was used in place of the antisera as an
agglutination control. Agglutination as noted
visually or by dark field microscopy was considered
a positive serotype result for that isolate. Any
extract that failed to agglutinate or demonstrated
agglutination in the PBS control was repeated.
GBS isolates were labeled as nontypeable (NT) if
they failed to agglutinate with any of the antisera or
repeatedly agglutinated in all antisera and the PBS
control.
Statistical analysis
Statistical analysis was performed using SigmaStat
(Jandel Scientific, San Rafael, CA). Chi-square
was used for comparisons of serotype frequency
between reproductive and non-reproductive-age
females, pregnant and nonpregnant females,
isolation from the vagina versus the urine and
females with vaginitis versus females with no
symptoms.
RESULTS
One hundred and seven GBS isolates were
obtained from patients at a community hospital in
Huntington, WV. The GBS serotype frequencies
categorized by patient sex and age, as well as isola-
tion from the vagina or urine, are shown in
Table 1. Serotypes Ia, V and III were the most
common in this population with frequencies of
23, 21 and 20% respectively. Serotype IV was the
least frequent, accounting for only 5% of the total
number of GBS isolates. Nine percent of the
isolates were nontypeable by agglutination.
Restriction fragment length polymorphism
analysis on the capsule locus, as described previ-
ously by Sellin and colleagues2, was attempted to
assign serotypes to the NT isolates. However,
this method failed to provide any additional
information (data not shown).
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The majority of isolates were obtained from
reproductive-age women (73%) while males
accounted for only 5% of the total. In the male
population, serotype III was most commonly iso-
lated. No statistical comparisons between the
female and male serotype distributions were made
due to the small number of GBS isolates from
males (n = 5). In reproductive-age females,
serotype Ia was the most frequent, while serotype
V was most frequent in non-reproductive-age
females. However, the individual serotype fre-
quencies between these two groups were not
significantly different (p = 0.273) (Table 1).
Additional comparisons made with respect to
pregnancy status (p = 0.239), site of isolation
(vaginal versus urine; p = 0.71), and symptomatic
vaginitis (versus asymptomatic females; p = 0.511)
revealed no significant differences.
Eleven percent of the women in this study had
infants with neonatal intensive care unit visits.
None of these infants was under observation for
GBS infection. All six GBS serotypes were isolated
from these women; however, serotypes Ib, II and
V were most frequent with three isolates each. In
addition, the five females with previous positive
GBS cultures were also carrying isolates of the
most common serotypes: Ia (n = 2); III (n = 1);
and V (n = 2).
DISCUSSION
It has been well documented that antibodies to
GBS-serotype-specific capsule polysaccharide are
protective3,4. Unfortunately, few individuals
generate sufficient quantities of these antibodies.
Recent attempts at designing a vaccine against
serotype III GBS yielded less than ideal results with
only 40% of women vaccinated generating
antitype III antibodies5. Protein carriers, including
the tetanus toxoid6, are being evaluated for their
ability to enhance the immunogenicity of the
GBS capsule polysaccharide. Although such a
protein–polysaccharide conjugate vaccine shows
promise, a vaccine against multiple GBS serotypes
will be most efficacious. Harrison and colleagues2
report that a pentavalent vaccine against serotypes
Ia, Ib, II, III and V would protect approximately
95% of their study population.
The optimal design for a multivalent GBS
vaccine will include the most common capsule
polysaccharide serotypes. To date, much of the
data regarding GBS serotype distribution has been
obtained from large centers. The purpose of our
study was to determine the serotype frequencies in
a small community hospital in West Virginia and to
compare our data to those from larger North
American centers.
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Females
Age (years) Isolation site
Serotype Males < 13 13–39 > 39 Vagina* Urine** Percent of total
Ia
Ib
II
III
IV
V
NT
1
1
0
2
0
1
0
0
2
0
2
0
1
0
21
11
8
15
4
14
5
3
1
1
2
1
6
5
19
13
9
15
4
15
9
5
1
0
3
1
4
1
23
14
8
20
5
21
9
*GBS were isolates from swabs taken from the lower third of the vagina and the rectum for pregnant females, while swabs were taken
from the vagina only for symptomatic, nonpregnant women; **urine specimens were considered positive for GBS when > 10 000
colony-forming units were present; NT, nontypeable
Table 1 GBS serotypes by patients’ sex, age and site of isolation
Comparison of the West Virginia serotype
frequencies with those observed primarily in adults
or pregnant women from Maryland7; Iowa8;
Texas9; Alberta, Canada10; and Calgary, Canada11
is shown in Table 2. The three most common
serotypes in our study and the others are Ia, III and
V with the exception of Texas where Ia, II and III
were the most prevalent. While serotype IV was
least common in all populations, in our study it
accounted for 5% of the total number of isolates,
which differs from the other study populations that
report frequencies of 0–2%. Although this differ-
ence is slight, it might indicate that serotype IV
GBS is an emerging serotype in our community.
This trend should be monitored in the future as a
shift in the serotype distributions may alter efficacy
of a potential vaccine. Nontypeable isolate
frequencies ranged from 3 to 13% in the large
North American centers. Our West Virginia
population was 9% nontypeable.
Of the centers with which we compared our
data, our population most closely resembles those
from Canada. Yet overall the serotype distribution
in our West Virginia community does not differ
greatly from any of the larger centers. As such, the
pentavalent vaccine proposed by Harrison2 would
be effective in protecting at least 86% of our
population. Based on this study, we are confident
that our community is similar enough to large
metropolitan areas that a multivalent vaccine
designed from serotype frequencies in these
communities would also be effective for our area.
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9
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5
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9
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< 1
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4
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6
5
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0
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3
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9
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24
0
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4
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10
9
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0
31
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2.1
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11.2
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